2,5-二氯-4-氨基吡啶 | 405230-82-2

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2,5-二氯-4-氨基吡啶
• 中文别名: 2,5-二氯吡啶-4-胺
• 英文名称: 2,5-dichloropyridin-4-amine
• 英文别名: 2,5-dichloro-4-amino-pyridine
• CAS: 405230-82-2
• 化学式: C₅H₄Cl₂N₂
• mdl: MFCD11044256
• 分子量: 163.006
• InChiKey: HBJPCBYDFZOSOT-UHFFFAOYSA-N

物化性质

• 熔点：
  125.5-126℃
• 沸点：
  294.3±35.0 °C(Predicted)
• 密度：
  1.497±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  应存放在2-8°C的环境中，避免光照，并保存在惰性气体中。

反应信息

• 作为反应物：
  描述：

  2,5-二氯-4-氨基吡啶 在 硫酸 、 potassium nitrate 作用下， 以65%的产率得到2,5-dichloro-4-nitraminopyridine
  参考文献：
  名称：

  SYNTHESIS OF HALOGEN-SUBSTITUTED 3-DEAZAADENOSINE AND 3-DEAZAGUANOSINE ANALOGUES AS POTENTIAL ANTITUMOR/ANTIVIRAL AGENTS

  摘要：

  Various 2-halogen-substituted analogues (38, 39, 43 and 44), 3-halogen-substituted analogues (51 and 52), and 2',3'-dihalogen-substituted analogues (57-60) of 3-deazaadenosine and 3-halogen-substituted analogues (61 and 62) of 3-deazaguanosine have been synthesized as potential anticancer and/or antiviral agents. Among these compounds, 3-deaza-3-bromoguanosine (62) showed significant cytotoxicity against L1210, P388, CCRF-CEM and B16F10 cell lines in vitro, producing IC50 values of 3, 7, 9 and 7 muM, respectively. Several 3-deazaadenosine analogues (38, 51, 57 and 59) showed moderate to weak activity against hepatitis B virus.

  DOI：

  10.1081/ncn-100108327
• 作为产物：
  描述：

  2,5-二氯吡啶 在 镍 硫酸 、 氢气 、 双氧水 、 potassium nitrate 、 三氟乙酸 作用下， 以 乙醇 为溶剂， 生成 2,5-二氯-4-氨基吡啶
  参考文献：
  名称：

  SYNTHESIS OF HALOGEN-SUBSTITUTED 3-DEAZAADENOSINE AND 3-DEAZAGUANOSINE ANALOGUES AS POTENTIAL ANTITUMOR/ANTIVIRAL AGENTS

  摘要：

  Various 2-halogen-substituted analogues (38, 39, 43 and 44), 3-halogen-substituted analogues (51 and 52), and 2',3'-dihalogen-substituted analogues (57-60) of 3-deazaadenosine and 3-halogen-substituted analogues (61 and 62) of 3-deazaguanosine have been synthesized as potential anticancer and/or antiviral agents. Among these compounds, 3-deaza-3-bromoguanosine (62) showed significant cytotoxicity against L1210, P388, CCRF-CEM and B16F10 cell lines in vitro, producing IC50 values of 3, 7, 9 and 7 muM, respectively. Several 3-deazaadenosine analogues (38, 51, 57 and 59) showed moderate to weak activity against hepatitis B virus.

  DOI：

  10.1081/ncn-100108327

文献信息

• [EN] TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF<br/>[FR] INHIBITEURS TRICYCLIQUES DE L'INTERACTION PROTÉINE-PROTÉINE DU DOMAINE BTB DE BCL6 ET UTILISATIONS ASSOCIÉES
  申请人：ONTARIO INSTITUTE FOR CANCER RES OICR

  公开号：WO2019119145A1

  公开（公告）日：2019-06-27

  The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

  本申请涉及式(I)的化合物或其药用可接受的盐、溶剂化合物和/或前药，包括含有这些化合物或其药用可接受的盐、溶剂化合物和/或前药的组合物，以及在治疗可通过抑制与BCL6 BTB的相互作用可治疗的疾病、紊乱或状况中的各种用途，如癌症。
• [EN] CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS<br/>[FR] CARBOXAMIDES UTILISÉS EN TANT QU'INHIBITEURS DES CANAUX SODIQUES
  申请人：VERTEX PHARMA

  公开号：WO2019014352A1

  公开（公告）日：2019-01-17

  Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

  提供了作为钠通道抑制剂的化合物及其药用盐。还提供了包含这些化合物或药用盐的药物组合物，以及使用这些化合物、药用盐和药物组合物治疗各种疾病，包括疼痛的方法。
• [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS
  申请人：FOGHORN THERAPEUTICS INC

  公开号：WO2021155320A1

  公开（公告）日：2021-08-05

  The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

  本公开涉及用于治疗BAF复合物相关疾病的化合物。
• [EN] INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF<br/>[FR] INHIBITEURS DE L'INTERACTION PROTÉINE-PROTÉINE DU DOMAINE BCL6 BTB ET LEURS UTILISATIONS
  申请人：ONTARIO INSTITUTE FOR CANCER RES OICR

  公开号：WO2019153080A1

  公开（公告）日：2019-08-15

  The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

  本申请涉及公式I（I）化合物或其药用可接受的盐、溶剂化合物和/或前药，包括含有这些化合物或药用可接受的盐、溶剂化合物和/或前药的组合物，以及在治疗可通过抑制与BCL6 BTB的相互作用可治疗的疾病、紊乱或状况中的各种用途，如癌症。
• Novel nucleosides and related processes, pharmaceutical compositions and methods
  申请人：——

  公开号：US20040116362A1

  公开（公告）日：2004-06-17

  The invention provides novel nucleosides and related processes, pharmaceutical compositions, and methods. The novel nucleosides are useful in a wide variety of antiviral, antineoplastic, and antibacterial applications. Preferred embodiments of the instant invention include novel 2 halogen-substituted, 3 halogen-substituted, and 2′,3′dihalogen-substituted analogues of 3-deazaadenosine, and novel 3 halogen-substituted analogues of 3-deazaguanosine. Compounds of the instant invention, including 4-Amino-6-fluoro-1-(&bgr;-D-ribofuranosyl)imidazo[4,5-c]pyridine and 6-Amino-7-bromo-1,5-dihydro-1-&bgr;- D -ribofuranosylimidazo[4,5-c]pyridin-4-one, have exhibited potent antiviral and anticancer activity in vitro. The compounds are also useful in the concomitant treatment of bacterial infections associated with viral infections such as AIDS.

  该发明提供了新颖的核苷和相关的工艺、药物组合和方法。这些新颖的核苷在抗病毒、抗肿瘤和抗菌应用中非常有用。该发明的首选实施例包括新型的2卤代、3卤代和2′,3′二卤代的3-去氨腺苷类似物，以及新型的3卤代的3-去氨鸟苷类似物。该发明的化合物，包括4-氨基-6-氟-1-(&bgr;-D-核糖呋喃基)咪唑[4,5-c]吡啶和6-氨基-7-溴-1,5-二氢-1-&bgr;-D-核糖基咪唑[4,5-c]吡啶-4-酮，在体外表现出强效的抗病毒和抗癌活性。这些化合物也在同时治疗与艾滋病等病毒感染相关的细菌感染方面非常有用。